Author

Suhail Nurbhai

Observed names: S Nurbhai, S. NURBHAI

Institution: Mission Therapeutics (United Kingdom)

Observed institutions: Mayo Clinic, Ninewells Hospital, Mission Therapeutics (United Kingdom), VHsquared (United Kingdom)

ORCID: 0000-0002-4218-9599

Observed ORCID: 0000-0002-4218-9599

OpenAlex ID: A5047453506

Cell death in granulomata: the role of apoptosis.

1987 · I A Cree, S Nurbhai, et al. · Journal of Clinical Pathology · 71

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients

2019 · Suhail Nurbhai, Kevin J. Roberts, et al. · Scientific Reports · 40

A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double‐blind, placebo‐controlled pharmacodynamic study

2007 · R. S. CHOUNG, D. D. FERGUSON, et al. · Alimentary Pharmacology & Therapeutics · 19

T1397 A Novel, Oral 5HT3 Partial Agonist, DDP733, Improves Overall Response in Patients with Irritable Bowel Syndrome and Constipation (IBS-c): A Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study

2008 · William G. Paterson, David Ford, et al. · Gastroenterology · 9

377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)

2008 · William G. Paterson, Jonathon Springer, et al. · Gastroenterology · 5

MTX652, a Novel Selective USP30 Inhibitor for the Treatment of AKI: Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections

2023 · Pau Aceves, Paul W. Thompson, et al. · Journal of the American Society of Nephrology · 4

P668 Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD

2018 · S Nurbhai, M West, et al. · Journal of Crohn s and Colitis · 2

Abstract 4135531: The Ubiquitin-Specific Protease 30 Inhibitor, MTX652, Attenuates Cardiac Dysfunction And Remodelling In a Murine Model Of Transverse Aortic Constriction

2024 · Rebecca Dunmore, Zoe Haines, et al. · Circulation · 1

ADTU-02 V565, a novel oral anti-TNF domain antibody, reduces colonic mucosal inflammation in patients with UC

2018 · Gareth Parkes, Suhail Nurbhai, et al. · Gut · 1

Phase I trial code: RD 787.36057 (MTX325-101)

2024 · Suhail Nurbhai, Natalie Jones, et al. · http://isrctn.com/

A Protease-stabilised Oral Domain Antibody to TNF Delivers High Concentrations of Active Compound in Ileal Fluid of Subjects with an Ileostomy

2017 · Suhail Nurbhai

A Novel Partial 5HT3 Agonist DDP733 after a Standard Refluxogenic Meal Reduces Reflux Events: A Randomized, Double-Blind, Placebo-Controlled Pharmacodynamic Study

2007 · Rok Seon Choung, Dawn D. Ferguson, et al. · The American Journal of Gastroenterology

Works count: 12

Citation count: 152

H-index: 5

I10-index: 3